Reply: Evaluating the activity of temsirolimus in neuroendocrine cancer

[1]  Zhiguo Li,et al.  Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design , 2006, Clinical trials.

[2]  R. Motzer,et al.  Sunitinib in patients with metastatic renal cell carcinoma. , 2006, JAMA.

[3]  G. Rosner,et al.  Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Richard Simon,et al.  Evaluation of randomized discontinuation design. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  G. Rosner,et al.  Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  E Marubini,et al.  Content and quality of currently published phase II cancer trials. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.